Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma

Jonathan L. Berkowitz, John E. Janik, Donn M. Stewart, Elaine S. Jaffe, Maryalice Stetler-Stevenson, Joanna H. Shih, Thomas A. Fleisher, Maria Turner, Nicole E. Urquhart, Gilian H. Wharfe, William D. Figg, Cody J. Peer, Carolyn K. Goldman, Thomas A. Waldmann, John C. Morris

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Interleukin-2 receptor α chain (CD25) is overexpressed in human T-cell leukemia virus 1 associated adult T-cell leukemia/lymphoma (ATL). Daclizumab a humanized monoclonal antibody blocks IL-2 binding by recognizing the interleukin-2 receptor α chain (CD25). We conducted a phase I/II trial of daclizumab in 34 patients with ATL. Saturation of surface CD25 on circulating ATL cells was achieved at all doses; however saturation on ATL cells in lymph nodes required 8. mg/kg. Up to 8. mg/kg of daclizumab administered every 3. weeks was well tolerated. No responses were observed in 18 patients with acute or lymphoma ATL; however, 6 partial responses were observed in 16 chronic and smoldering ATL patients. The pharmacokinetics/pharmacodynamics of daclizumab suggest that high-dose daclizumab would be more effective than low-dose daclizumab in treatment of lymphoid malignancies and autoimmune diseases (e.g., multiple sclerosis) since high-dose daclizumab is required to saturate IL-2R alpha in extravascular sites.

Original languageEnglish (US)
Pages (from-to)176-187
Number of pages12
JournalClinical Immunology
Volume155
Issue number2
DOIs
StatePublished - Dec 1 2014

Fingerprint

Adult T Cell Leukemia Lymphoma
Pharmacokinetics
Safety
Interleukin-2 Receptors
Deltaretrovirus
Antibodies, Monoclonal, Humanized
daclizumab
Autoimmune Diseases
Multiple Sclerosis
Interleukin-2
Lymphoma
Lymph Nodes

Keywords

  • Adult T-cell leukemia/lymphoma
  • Daclizumab
  • Human T-cell leukemia virus 1 (HTLV-1) associated ATL
  • Interleukin-2 receptor alpha
  • Monoclonal antibody

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Berkowitz, J. L., Janik, J. E., Stewart, D. M., Jaffe, E. S., Stetler-Stevenson, M., Shih, J. H., ... Morris, J. C. (2014). Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. Clinical Immunology, 155(2), 176-187. https://doi.org/10.1016/j.clim.2014.09.012

Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. / Berkowitz, Jonathan L.; Janik, John E.; Stewart, Donn M.; Jaffe, Elaine S.; Stetler-Stevenson, Maryalice; Shih, Joanna H.; Fleisher, Thomas A.; Turner, Maria; Urquhart, Nicole E.; Wharfe, Gilian H.; Figg, William D.; Peer, Cody J.; Goldman, Carolyn K.; Waldmann, Thomas A.; Morris, John C.

In: Clinical Immunology, Vol. 155, No. 2, 01.12.2014, p. 176-187.

Research output: Contribution to journalArticle

Berkowitz, JL, Janik, JE, Stewart, DM, Jaffe, ES, Stetler-Stevenson, M, Shih, JH, Fleisher, TA, Turner, M, Urquhart, NE, Wharfe, GH, Figg, WD, Peer, CJ, Goldman, CK, Waldmann, TA & Morris, JC 2014, 'Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma', Clinical Immunology, vol. 155, no. 2, pp. 176-187. https://doi.org/10.1016/j.clim.2014.09.012
Berkowitz, Jonathan L. ; Janik, John E. ; Stewart, Donn M. ; Jaffe, Elaine S. ; Stetler-Stevenson, Maryalice ; Shih, Joanna H. ; Fleisher, Thomas A. ; Turner, Maria ; Urquhart, Nicole E. ; Wharfe, Gilian H. ; Figg, William D. ; Peer, Cody J. ; Goldman, Carolyn K. ; Waldmann, Thomas A. ; Morris, John C. / Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. In: Clinical Immunology. 2014 ; Vol. 155, No. 2. pp. 176-187.
@article{5d9e6a4f193f4103a406e0a47442c794,
title = "Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma",
abstract = "Interleukin-2 receptor α chain (CD25) is overexpressed in human T-cell leukemia virus 1 associated adult T-cell leukemia/lymphoma (ATL). Daclizumab a humanized monoclonal antibody blocks IL-2 binding by recognizing the interleukin-2 receptor α chain (CD25). We conducted a phase I/II trial of daclizumab in 34 patients with ATL. Saturation of surface CD25 on circulating ATL cells was achieved at all doses; however saturation on ATL cells in lymph nodes required 8. mg/kg. Up to 8. mg/kg of daclizumab administered every 3. weeks was well tolerated. No responses were observed in 18 patients with acute or lymphoma ATL; however, 6 partial responses were observed in 16 chronic and smoldering ATL patients. The pharmacokinetics/pharmacodynamics of daclizumab suggest that high-dose daclizumab would be more effective than low-dose daclizumab in treatment of lymphoid malignancies and autoimmune diseases (e.g., multiple sclerosis) since high-dose daclizumab is required to saturate IL-2R alpha in extravascular sites.",
keywords = "Adult T-cell leukemia/lymphoma, Daclizumab, Human T-cell leukemia virus 1 (HTLV-1) associated ATL, Interleukin-2 receptor alpha, Monoclonal antibody",
author = "Berkowitz, {Jonathan L.} and Janik, {John E.} and Stewart, {Donn M.} and Jaffe, {Elaine S.} and Maryalice Stetler-Stevenson and Shih, {Joanna H.} and Fleisher, {Thomas A.} and Maria Turner and Urquhart, {Nicole E.} and Wharfe, {Gilian H.} and Figg, {William D.} and Peer, {Cody J.} and Goldman, {Carolyn K.} and Waldmann, {Thomas A.} and Morris, {John C.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.clim.2014.09.012",
language = "English (US)",
volume = "155",
pages = "176--187",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma

AU - Berkowitz, Jonathan L.

AU - Janik, John E.

AU - Stewart, Donn M.

AU - Jaffe, Elaine S.

AU - Stetler-Stevenson, Maryalice

AU - Shih, Joanna H.

AU - Fleisher, Thomas A.

AU - Turner, Maria

AU - Urquhart, Nicole E.

AU - Wharfe, Gilian H.

AU - Figg, William D.

AU - Peer, Cody J.

AU - Goldman, Carolyn K.

AU - Waldmann, Thomas A.

AU - Morris, John C.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Interleukin-2 receptor α chain (CD25) is overexpressed in human T-cell leukemia virus 1 associated adult T-cell leukemia/lymphoma (ATL). Daclizumab a humanized monoclonal antibody blocks IL-2 binding by recognizing the interleukin-2 receptor α chain (CD25). We conducted a phase I/II trial of daclizumab in 34 patients with ATL. Saturation of surface CD25 on circulating ATL cells was achieved at all doses; however saturation on ATL cells in lymph nodes required 8. mg/kg. Up to 8. mg/kg of daclizumab administered every 3. weeks was well tolerated. No responses were observed in 18 patients with acute or lymphoma ATL; however, 6 partial responses were observed in 16 chronic and smoldering ATL patients. The pharmacokinetics/pharmacodynamics of daclizumab suggest that high-dose daclizumab would be more effective than low-dose daclizumab in treatment of lymphoid malignancies and autoimmune diseases (e.g., multiple sclerosis) since high-dose daclizumab is required to saturate IL-2R alpha in extravascular sites.

AB - Interleukin-2 receptor α chain (CD25) is overexpressed in human T-cell leukemia virus 1 associated adult T-cell leukemia/lymphoma (ATL). Daclizumab a humanized monoclonal antibody blocks IL-2 binding by recognizing the interleukin-2 receptor α chain (CD25). We conducted a phase I/II trial of daclizumab in 34 patients with ATL. Saturation of surface CD25 on circulating ATL cells was achieved at all doses; however saturation on ATL cells in lymph nodes required 8. mg/kg. Up to 8. mg/kg of daclizumab administered every 3. weeks was well tolerated. No responses were observed in 18 patients with acute or lymphoma ATL; however, 6 partial responses were observed in 16 chronic and smoldering ATL patients. The pharmacokinetics/pharmacodynamics of daclizumab suggest that high-dose daclizumab would be more effective than low-dose daclizumab in treatment of lymphoid malignancies and autoimmune diseases (e.g., multiple sclerosis) since high-dose daclizumab is required to saturate IL-2R alpha in extravascular sites.

KW - Adult T-cell leukemia/lymphoma

KW - Daclizumab

KW - Human T-cell leukemia virus 1 (HTLV-1) associated ATL

KW - Interleukin-2 receptor alpha

KW - Monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=84910096506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910096506&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2014.09.012

DO - 10.1016/j.clim.2014.09.012

M3 - Article

VL - 155

SP - 176

EP - 187

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -